Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia

NCT06566885 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06566885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06566885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
September 10, 2024
Completion date
September 30, 2026
Enrollment
125 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma